CD20 Clinical Trials

6 recruitingLast updated: May 21, 2026

There are 6 actively recruiting cd20 clinical trials across 4 countries. Studies span Phase 2, Phase 1, Phase 3, Phase 4. Top locations include Brzozów, Poland, Gliwice, Poland, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


CD20 Trials at a Glance

6 actively recruiting trials for cd20 are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Brzozów, Gliwice, and Guangzhou. Lead sponsors running cd20 studies include Guangzhou Excelmab Inc., Li Zhiming, and Maria Sklodowska-Curie National Research Institute of Oncology.

Browse cd20 trials by phase

About CD20 Clinical Trials

Looking for clinical trials for CD20? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CD20 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CD20 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaBurkitt Lymphoma+3 more
New York Medical College25 enrolled1 locationNCT02393157
Recruiting
Phase 2

Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL

Initial MZLUntreated MZLBTKi+1 more
Li Zhiming33 enrolled2 locationsNCT06985472
Recruiting
Phase 2

Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

CD20-positive Acute Lymphoblastic Leukemia
Maria Sklodowska-Curie National Research Institute of Oncology124 enrolled19 locationsNCT04920968
Recruiting
Phase 1Phase 2

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

CD20-positive Non-Hodgkin Lymphoma
Guangzhou Excelmab Inc.415 enrolled4 locationsNCT06021678
Recruiting
Phase 2

Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)

Resolved Hepatitis BCD20 Positive B-cell Lymphoma
Sun Yat-sen University84 enrolled1 locationNCT05453435
Recruiting
Phase 3Phase 4

Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant study

Relapsed or refractory CD20 positive diffuse large B-cell lymphoma
Roche40 enrolled1 locationACTRN12606000373572